中国现代医学杂志2017，Vol.27Issue(8)：59-65,7.DOI:10.3969/j.issn.1005-8982.2017.08.013
哌拉西林他唑巴坦在重症患者的肺组织渗透性
Pulmonary penetration in critically ill patients with piperacillin and tazobactam
黄琳惠 1黄奕江 1敬攀 2冀延春3
作者信息
- 1. 海南省人民医院 呼吸内科,海南 海口 570311
- 2. 浙江省宁波市康宁医院 心身科,浙江 宁波 315201
- 3. 浙江大学 遗传学研究所,浙江 杭州310058
- 折叠
摘要
Abstract
Objective To quantify the pulmonary penetration of piperacillin and tazobactam in critically ill patients and to investigate factors that may influence the penetration of drug into the lung. Methods The plasma and intrapulmonary pharmacokinetics (PK) of piperacillin-tazobactam in critically ill patients administered standard piperacillin- tazobactam regimens were studied. A population PK model was developed to describe plasma and intrapulmonary piperacillin and tazobactam concentrations. The probability of piperacillin exposures reaching pharmacodynamic end points and the impact of pulmonary permeability on piperacillin and tazobactam pulmonary penetration were explored. Results The median piperacillin and tazobactam pulmonary penetration ratios were 49.3 and 121.2%, respectively. Pulmonary piperacillin and tazobactam concentrations were un-predictable and negatively correlated with pulmonary permeability. Conclusions Current piperacillin-tazobactam regimens may be insufficient to treat pneumonia caused bypiperacillin-tazobactam- susceptible organisms in some critically ill patients.关键词
哌拉西林/他唑巴坦/群体药代动力学/重症/肺炎Key words
piperacillin/tazobactam/population pharmacokinetics/severe case/pneumonia分类
医药卫生引用本文复制引用
黄琳惠,黄奕江,敬攀,冀延春..哌拉西林他唑巴坦在重症患者的肺组织渗透性[J].中国现代医学杂志,2017,27(8):59-65,7.
